002422.SZSichuan Kelun Pharmaceutical Co., Ltd. Class A
The schedule
- Thu15Oct
Expected readout for the company's TROP2 ADC pipeline assets and ongoing partnerships at a major Q4 oncology conference, framing a directional move to $44.00 or $33.00.
- Tue3Nov
Q3 2026 results release assessing the sequential revenue stabilization and cash flow optimization, targeting $49.50 on execution or $39.00 on margin deterioration.
- Tue15Dec
Annual China NRDL negotiations defining 2027 pricing tiers for the company's marketed drugs, resolving pricing uncertainty with a projected band of $54.50 to $42.00.
- Tue20Apr
Full-year 2026 audit and initial FY 2027 management outlook, testing the structural transition from generics to innovatives with a valuation span of $48.00 to $36.00.
Past
- Fri28Aug
Actual outcome: Bear · $40.65 at outcome
Price reached or fell below bear floor ($38.00) at outcome date.
Kelun Pharma's 1H 2026 financial print will test the current 44.8x P/E multiple against ongoing core IV solution pricing headwinds, charting a path toward either $49.00 or $38.00.